论文部分内容阅读
在国内仿制药兴起的背景下.为了适应愈演愈烈的市场竞争环境.外资药企正在集中处理旗下盈利能力较差的产品线.并将资源用于高新原研药的研发。同时.为了符合“合规性”的要求.外资药企正在组团进入转型期。继2014年底在中国进行千人大裁员后,近日,美国药企百时美施贵宝再次曝出裁员计划.被裁员的主要部门涉及肿瘤事业部的两个产品组,包括泰素(紫杉醇注射液)和伯尔定(卡铂注射液)两个产品部门均受到影响,裁员总数近干入。此外,今年3月,百时美施贵宝同时停止在中国区所有业务部门的客户招待,讲课费,学会赞助等活动,以适应中国区对外资药企合规性的要
In the context of the rise of generic drugs in China, in order to adapt to the increasingly competitive market environment, foreign pharmaceutical companies are concentrating on their poor profitability product lines and resources for research and development of new and high-tech original drugs. At the same time, in order to meet the requirements of “compliance”, foreign pharmaceutical companies are moving into a transition period. Following the massive layoffs by thousands of people in China at the end of 2014, the U.S. pharmaceutical company Bacer recently exposed the layoffs again, involving two major product divisions, Taxol (Paclitaxel Injection) and Cancer Products Burdin (carboplatin injection) both product sectors are affected, the total number of layoffs nearly dry into. In addition, in March this year, Bristol-Myers Squibb ceased all client services, lecture fees, and academic sponsorship in all business areas in China to meet the regulatory requirements for foreign-funded pharmaceutical enterprises in China